evaluating of clobetasol 0.05% and doxepine 5% cream vs clobetasol 0.05% and placebo in the treatment of moderate to severe hand eczema

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112018263N1

Enrollment

Registered

2012-05-05

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hand eczema. Other atopic dermatitis

Interventions

Intervention 1: doxepine 5% cream and clobetasol 0.05% are applied twice a day for 8 days. Intervention 2: clobetasol 0.05% and placebo are applied twice a day for 8 days.

Treatment - Drugs

Placebo

doxepine 5% cream and clobetasol 0.05% are applied twice a day for 8 days

clobetasol 0.05% and placebo are applied twice a day for 8 days

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:all patients with moderate to severe hand eczema that are 12 to 70 years old exclusion criteria:treatment with systemic steroid less than 1 month before trial;treatment with topical steroid and antihistamines at the time of presentation ;pregnancy;lactatation;age less than 12

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduction or improvement of hand eczema. Timepoint: before and 8 days after treatment. Method of measurement: hand eczema severity index.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: 8 days after initiation of treatment. Method of measurement: 8 days after initiation of treatment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarideh Dehghani, MD

?Shahid Sadooghi University of Medical Sciences,Yazd

farideh.dehghan@ssu.ac.ir+98 35 1525 0093

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026